Elad Sharon: Another win for patients with ALL

Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared on X:

“Another win for NCI, NCI CTEP Clinical Research, ECOG-ACRIN Cancer Research Group, but especially for patients with ALL! Amazing results with Amgen’s blinatumomab and for immunotherapy! Already approved by FDA Oncology...”

Source: Elad Sharon/X